WOBURN, Mass.– Orogen Therapeutics has entered a strategic collaboration with Chemspace and Enamine to accelerate the design and development of novel small molecule therapies using next-generation DNA-encoded library (DEL) technology. The partnership aims to leverage each company’s strengths to push the boundaries of DEL screening and drug discovery.
The alliance will combine Orogen’s proprietary AI-enabled DEL platform with Chemspace’s chemoinformatics expertise and Enamine’s extensive REAL (REadily AccessibLe) compound collection—the world’s largest make-on-demand chemical space. The three firms plan to co-design and synthesize new DELs, enabling faster and more efficient screening for potential treatments targeting conditions such as immuno-inflammatory disorders, GPCRs, and select oncology indications.
“We are thrilled to engage in this strategic collaboration to drive new horizons for DEL-based drug development,” said Mark Pykett, CEO of Orogen Therapeutics. “The synergy of Chemspace-Enamine’s REAL chemical space and our AI-enabled DEL capabilities offers powerful potential to enhance and accelerate small molecule drug discovery.”
Under the agreement, Chemspace and Orogen will co-design DELs based on REAL principles, while Chemspace and Enamine will handle synthesis and analytical validation. Orogen will then conduct pilot screenings across a range of biological targets, using its proprietary FocusDEL™ technology to identify promising drug candidates from billions of compound variations.
DEL screening is a well-established approach for efficiently exploring large swaths of chemical space to find new molecular hits. By integrating Chemspace’s make-on-demand capabilities and Enamine’s vast chemical inventory, the collaboration seeks to streamline the often time-consuming path from hit identification to structure-activity relationship (SAR) development and compound optimization.
“This collaboration will add much-needed next-generation DELs to the drug discovery toolbox,” said Dr. Artem Evdokimov, Orogen’s head of research. “Harmonizing DEL design with REAL Space chemistry allows for rapid, economical synthesis of both initial hits and related analogs—accelerating early-stage development.”
Dr. Sven Wagner, VP of Partnerships at Enamine, highlighted the broader impact: “This partnership enriches the DEL field by providing a critical, ready-to-synthesize chemical space. It helps researchers across the globe move faster toward treatments for patients with high unmet needs.”
Chemspace CEO Dr. Olga Tarkhanova echoed the sentiment: “By applying scalable, make-on-demand chemistry to DEL design, we are addressing a key bottleneck—bridging the gap from encoded hits to optimized drugs. This collaboration represents a step forward in simplifying off-DNA synthesis and accelerating the DMTA (design–make–test–analyze) cycle.”
With DEL technology increasingly recognized as a powerful tool for drug discovery, the partnership between Orogen, Chemspace, and Enamine marks a significant step toward unlocking new therapeutic possibilities through data-driven innovation and vast chemical accessibility.
